Management of bronchiectasis in adults

Simone K Visser, Peter Bye and Lucy Morgan
Med J Aust 2018; 209 (4): . || doi: 10.5694/mja17.01195
Published online: 20 August 2018



  • Once neglected in research and underappreciated in practice, there is renewed interest in bronchiectasis unrelated to cystic fibrosis.
  • Bronchiectasis is a chronic lung disease characterised by chronic cough, sputum production and recurrent pulmonary exacerbations. It is diagnosed radiologically on high resolution computed tomography chest scan by bronchial dilatation (wider than the accompanying artery).
  • The causes of bronchiectasis are diverse and include previous respiratory tract infections, chronic obstructive pulmonary disease, asthma, immunodeficiency and connective tissue diseases. A large proportion of cases are idiopathic, reflecting our incomplete understanding of disease pathogenesis.
  • Progress in the evidence base is reflected in the 2017 European management guidelines and the 2015 update to the Australian guidelines.
  • Effective airway clearance remains the cornerstone of bronchiectasis management. This should be personalised and reviewed regularly by a respiratory physiotherapist.
  • There is now robust evidence for the long term use of oral macrolide antibiotics in selected patients to reduce exacerbation frequency.
  • The routine use of long term inhaled corticosteroids and/or long-acting bronchodilators should be avoided, unless concomitant chronic obstructive pulmonary disease or asthma exists.
  • The evidence for nebulised agents including hypertonic saline, mannitol and antibiotics is evolving; however, access is challenging outside tertiary clinics, and nebulising equipment is required.
  • Smokers should be supported to quit. All patients should receive influenza and pneumococcal vaccination. Patients with impaired exercise capacity should attend pulmonary rehabilitation.
  • There is an important minority of patients for whom aetiology-specific treatment exists.
  • The prevalence of bronchiectasis is increasing worldwide; however, the burden of disease within Australia is not well defined. To this end, the Australian Bronchiectasis Registry began recruitment in 2016 and is interoperable with the European and United States bronchiectasis registries to enable collaborative research.
  • The recent addition of a bronchiectasis diagnosis-related group to the Australian Refined Diagnostic Related Group classification system will allow definition of the disease burden within the Australian hospital system.


  • 1 Royal Prince Alfred Hospital, Sydney, NSW
  • 2 Concord Repatriation General Hospital, Sydney, NSW
  • 3 Sydney Medical School, University of Sydney, Sydney, NSW


Competing interests:

Lucy Morgan is Head of the Australian Bronchiectasis Registry Steering Committee.

  • 1. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629.
  • 2. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142: 432-439.
  • 3. Quint JK, Millett ERC, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47: 186-193.
  • 4. Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One 2013; 8: e71109.
  • 5. Singleton RJ, Valery PC, Morris P, et al. Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 2014; 49: 189-200.
  • 6. Chang AB, Grimwood K, Mulholland EK, et al. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002; 177: 200-204. <MJA full text>
  • 7. Bibby S, Milne R, Beasley R. Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand. N Z Med J 2015; 128: 30-38.
  • 8. Australian Consortium for Classification Development. AR-DRG Version 9.0 – final report. 1 Dec 2016. (viewed June 2018).
  • 9. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non–cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267.
  • 10. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
  • 11. Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2015; 202: 21-23. <MJA full text>
  • 12. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65(Suppl 1): i1-58.
  • 13. Tan WC, Hague CJ, Leipsic J, et al. Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study. PLoS ONE 2016; 11: e0166745.
  • 14. Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. Am J Roentgenol 2003; 180: 513-518.
  • 15. Gao YH, Guan WJ, Liu SX, et al. Aetiology of bronchiectasis in adults: a systematic literature review. Respirology 2016; 21: 1376-1383.
  • 16. Boyton RJ, Altmann DM. Bronchiectasis: current concepts in pathogenesis, immunology, and microbiology. Annu Rev Pathol 2016; 11: 523-554.
  • 17. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010; 193: 356-365. <MJA full text>
  • 18. McDonald CF, Whyte K, Jenkins S, et al. Clinical practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society of Australia and New Zealand: domiciliary oxygen guideline. Respirology 2016; 21: 76-78.
  • 19. Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47: 1113-1122.
  • 20. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 2015: CD008351.
  • 21. Thoracic Society of Australia and New Zealand. Bronchiectasis toolbox. (viewed June 2018).
  • 22. Lung Foundation Australia. Bronchiectasis. (viewed Mar 2018).
  • 23. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017; 72(Suppl 2): ii1-64.
  • 24. Spencer S, Felix LM, Milan SJ, et al. Oral versus inhaled antibiotics for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2017(3): CD012579.
  • 25. Kaehne A, Milan SJ, Felix LM, et al. Head-to-head trials of antibiotics for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2017(3): CD012590.
  • 26. Felix LM, Grundy S, Milan SJ, et al. Dual antibiotics for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2017(1): CD012514.
  • 27. Kelly C, Evans DJ, Chalmers JD, et al. Macrolide antibiotics for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2016(10): CD012406.
  • 28. Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest 2017; 151: 982-992.
  • 29. Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J 2017; 49: 1700051.
  • 30. Abo-Leyah H, Chalmers JD. New therapies for the prevention and treatment of exacerbations of bronchiectasis. Curr Opin Pulm Med 2017; 23: 218-224.
  • 31. Wilson R, Aksamit T, Aliberti S, et al. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respir Med 2016; 117: 179-189.
  • 32. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014; 44: 382-393.
  • 33. Xu L, Zhang F, Du S, et al. Inhaled antibiotics in non-cystic fibrosis bronchiectasis: a meta-analysis. Pharmazie 2016; 71: 491-498.
  • 34. Yang JW, Fan LC, Lu HW, et al. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. Clin Respir J 2016; 10: 731-739.
  • 35. Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
  • 36. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162(2 Pt 1): 481-485.
  • 37. Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
  • 38. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982.
  • 39. Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2: 738-749.
  • 40. Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 51: 1702053.
  • 41. De Soyza A, Aksamit T, Bandel T-J, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 2018; 51: 1702052.
  • 42. The European Bronchiectasis Registry. Results from RESPIRE 2 and ORBIT-3 and -4. (viewed June 2018).
  • 43. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non–cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259.
  • 44. Zhuo G-Y, He Q, Xiang-Lian L, et al. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials. Pulm Pharm Ther 2014; 29: 80-88.
  • 45. Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014; 19: 321-329.
  • 46. Yao G-Y, Ma Y-L, Zhang M-Q, Gao Z-C. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration 2013; 86: 254-260.
  • 47. Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med 2014; 108: 1397-1408.
  • 48. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non-Tuberculous) Committee of The Medical Research Council. Br Med J 1957; 2: 255-259.
  • 49. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990; 76: 799-816.
  • 50. Hill SL, Burnett D, Hewetson KA, Stockley RA. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med 1988; 66: 163-173.
  • 51. Daviskas E, Robinson M, Anderson SD, Bye PTP. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J Aerosol Med Pulm Drug Deliv 2002; 15: 331-341.
  • 52. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105: 1831-1835.
  • 53. Nicolson CHH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667.
  • 54. Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215-225.
  • 55. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69: 1073-1079.
  • 56. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998; 113: 1329-1334.
  • 57. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009(1): CD000996.
  • 58. Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141: 461-468.
  • 59. Wong C, Chang C, Lewis C, et al. Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial. Eur Respir J 2017; 50(Suppl 61).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.